Introduction
The central aim of genomic medicine is to utilize the individual's genomic information to support the clinical decision-making process [1] . In recent years, significant advances have been made in understanding the molecular etiology of a wide range of human genetic diseases. These advances have the potential to improve disease prognosis and treatment [2] . In parallel, genomic technology has progressed rapidly, prompting the replacement of low-throughput genetic screening methods by new high-throughput genomewide screening and massively parallel sequencing approaches [3] . As a result, genomics research has the potential to aid clinicians in their task of estimating disease risk, as well as individualizing treatment modalities. This constitutes the basis of Genomic Medicine, a new specialty that promises to enhance opportunities for the customization of patient care including the personalization of conventional therapeutic interventions [4] .
Although the concept of Genomic or Personalized Medicine is relatively new, its intellectual predecessors have been around for some considerable time. Thus, aAround 400 B.C.E., Hippocrates of Kos (460 B.C.-370 B.C.E.) stated that "… it is more important to know what kind of person suffers from a disease than to know the disease a person suffers".
AlsoIn addition, Ibn Sina (c.980-1037 C.E.) stated opined that "...in the make-up of most people there is somewhere a natural tendency to get out of order, some congenital weakness in one particular organ, tissue or system". Ibn Sina called termed this a "personal disposition"
and put forward the view that each patient is toshould be looked upon as a distinct and separate case. The first application of "Genomic Medicine" is codified in the Talmud. The Talmud (Yevamot 64b) relates Rabbi Judah the Prince's ruling [2 nd century B.C.E.] that if a woman's first two children had died from blood loss after circumcision, the third son should not be excused circumcisioned. Rabbi Simeon ben Gamliel disagreed and ruled that the third son mightay be circumcised, but if this infant also died then the fourth child should not be circumcised. These two Rabbis did however agreed that the abnormal bleeding tendency was hereditary, but disagreed as to how many repeatitive events were required to establish a pattern and thereforejustifying exemption of a child from circumcision.These ancient statements and examples together probably encapsulate the essence of modern personalized genomic medicine. At present, several international organizations and research consortia are harmonizing their efforts with a view toto the aim of supporting the translation of genomic research into clinical practice so that genomic medicine can ultimately be used to benefit the global community ( Table 1) .
The Genomic Medicine Alliance [GMA; 101] is a newly established global academic research network. It aims to build and strengthen collaborative ties between academics, researchers, regulators and those members of the general public who are interested in genomic medicine. The GMA focuses particularly on the translation of new research findings into clinical practice in developed, but most importantly, in developing countries. (Fig. 2) . Below, we summarize some of the key GMA research projects.
Aims and goals of the Genomic Medicine Alliance

Current research projects among GMA members
Genome Informatics Working Group
Documentation of the incidence of genetic disorders in different populations, particularly in those developing countries with a high incidence of genetic diseases and/or consanguinity can be particularly helpful in the context of adopting national prevention and screening programs [5] . GMA members currently participate in the development of three new National/Ethnic Genetic databases for the Kuwaiti, Moroccan and Bahraini populations to document the incidence of genetic disorders in these countries. In addition, five preexisting National/Ethnic Genetic databases for the Lebanese, Serbian, Cypriot, Greek and Egyptian populations are currently being migrated to the new ETHNOS software [6] , which has recently been upgraded to include new data querying and visualization functionalities [7] . The long-term goal is to expand this concept such that the ETHNOS software supports the development of several National Genetic databases [111] , based on the data warehouse principle and pre-existing guidelines [8] that will be assigned to senior human geneticists in the corresponding populations in order to coordinate their curation and further data [5] .
Members of the GMA have also helped to develop an electronic tool to translate pharmacogenomics research results into a format that is meaningful for clinicians [9] . Such a project is proceeding in close collaboration with other major European research initiatives, such as RD-Connect [112] in order to harmonize and develop common standards for databases and patient registries for rare diseases, and most importantly to develop clinical bioinformatics solutions, including data mining and knowledge discovery tools for the analysis and integration of molecular and clinical data to promote the discovery of new disease genes, pathways and therapeutic druggable targets.
Pharmacogenomics Working Group
Pharmacogenomics holds out the promise of rationalizing drug treatment by by optimizing the balance between treatment efficacy and toxicity based upon a comprehensive Preliminary findings suggest that European populations display functionally significant differences in terms of >130 pharmacogenomic biomarkers; the replication of these findings in larger population samples would establish a common framework for pharmacogenomic testing in developing countries.
The Pharmacogenomics Working Group has sought to provide proof-of-principle of the use of whole-genome sequencing for pharmacogenomic testing, by resequencing with high coverage almost 500 whole genomes, mostly from Caucasian populations. This project not only revealed a vast number of novel potentially functional variants in a total of 231 pharmacogenes, as indicated by in silico analysis, but also demonstrated the value of wholegenome sequencing for pharmacogenomic testing by capturing over 18,000 variants in these pharmacogenes; this compares with just 250 variants that would have been identified in these genes using the most comprehensive pharmacogenomics screening assay currently available [10] .
Public Health Genomics Working Group
Public Health Genomics represents the responsible and effective translation of genome-based knowledge and technologies into public policy and health services for the benefit of population health [11] . To this end, the Public Health Genomics Working Group is undertaking nationwide studies to better understand the level of the general public's genetics awareness including their attitudes to genomic testing and the level of healthcare professionals' (i.e. physicians, pharmacists, nutritionists, etc) genetics education. So far, such surveys have yielded some very interesting findings [12, 13] highlighting the relative lack of healthcare professionals' genetics education and general public's genetics awareness as perhaps one of the biggest obstacles to the widespread implementation of Genomic Medicine [14, 15] . They have also shown the plural general utilityies of genomic testing for individuals including the public's remarkable level of interest in participating in genomic research participation [16, 17] . Such surveys are currently being replicated in other European countries to confirm these findings. To this end, GMA members co-organize educational events revolving around pharmacogenomics and Genomic Medicine in various European countries; these are endorsed by the GMA and partly funded by the Golden Helix Foundation and other entities [18] .
The Public Health Genomics Working Group has engaged with a stakeholder analysis to determine the measures to be undertaken to expedite the genomic information-based medical decision-making process.
Genethics Working Group
Several ethical issues confront those of us who are committed to the practice of Genomic Medicine, including the regulation of genetic testing, the governance of genetic research, and genomic data sharing in an ethical and publicly accountable way [19] . The GMA Genethics Working group also explores the landscape of direct-to-consumer (DTC), beyond-the-clinic (BTC) [20] and over-the-counter (OTC) genetic tests in various European countries, including Greece [12] , Slovenia, Italy and Serbia. It is particularly important to harmonize policies that safeguard the general public and ensure that they are become better informed with respect to the various attendant risks from this type of testing. Currently, regulation ofn these issues is lacking in many European countries, as well as at a central level in the form of a directive of the European Medicines Agency for both OTC and DTC genetic testing [21] . The GMA has recently produced an opinion article to highlight the various types of OTC genetic tests currently available [22] . GMA members are also working together with the National Genetic Societies and National Ethics Committees to establish guidelines to cover ethical, legal and social issues pertaining to genetic testing.
Economic Evaluation in Genomic Medicine Working Group
A key factor in expediting the adoption of Genomic Medicine in clinical practice would be the demonstration of its cost-effectiveness (as the "fourth hurdle" in health care, after safety, efficacy and quality). The real cost effectiveness of involving genomics in medicine is unknown excepting certainapart from some rather limited studies in pharmacogenomics and hereditary cancer syndromes. Realizing its effectiveness would be a crucial step towards convincing policy makers of the utility of genomics in healthcare as a means to reduce the cost of treatments, as well as the overall burden and consequences of diseases at the national level [23, 24] . Currently, GMA members are involved in costeffectiveness and cost-utility analyses of warfarin (Croatia), acenocoumarol (Serbia and Greece) and clopidogrel (Serbia) anticoagulation treatments, and preliminary findings suggest that warfarin treatment is indeed cost-effective in Croatia [Mitropoulou C, Fragoulakis V, and co-workers, in preparation]. Future work is already in progress and includes drugs for cancer and hematologic malignancies treatment, while it is envisagedioned that the workgroup will eventually develop and evaluate standardized methodologies for economic evaluation of genomic medicine [25] , which will be of utmost importance in such a rapidly evolving discipline.
The GMA has recently endorsed the production of the textbook "Economic Evaluation in Genomic Medicine" that is co-authored by two GMA Scientific Advisory Committee members and will be published by Elsevier/Academic Press in early 2015.
Future perspectives: A roadmap of GMA activities
The GMA is a new initiative in the field of Genomic Medicine with the primary goal of encouraging the participation of developing and low-resourced countriessettings. In contrast to other Genomic Medicine initiatives and consortia (Table 1) policies and healthcare as a whole. This partnership not only provides GMA members with a highly respected publication forum for to publish their original research findings but also with discounts on journals and books.
Regarding the various ongoing GMA research activities, the focus will be firmly placed on those projects that will deliver tangible results in relation to the translation of genomics research into clinical practice, e.g., the elucidation of the molecular basis of rare disorders, bioinformatics solutions to translating genomic results into clinically meaningful formats and accommodating whole genome sequencing data storage in an aggregate manner.
Another, strong focal point for the next two years will be projects in the field of health economic evaluation in genomic medicine to study the cost-effectiveness of pharmacogenomic testing. In addition, and in order to support the transnational mobility of students and junior researchers, the GMA plans to launch short-and long-term research fellowships for early-stage researchers from developing countries to pursue research in In essence, the GMA, aspires to become a focal point for harmonizing research activities in the field of genomic medicine between developed and developing countries and while further cultivate helping to pave the way for a smoother transition from genomics research in to genomic medicine. 
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